H
Hiroyuki Mano
Researcher at University of Tokyo
Publications - 308
Citations - 24554
Hiroyuki Mano is an academic researcher from University of Tokyo. The author has contributed to research in topics: Gene & Cancer. The author has an hindex of 66, co-authored 275 publications receiving 22190 citations. Previous affiliations of Hiroyuki Mano include Astellas Pharma & Nagasaki University.
Papers
More filters
Journal ArticleDOI
Circulating late‐stage erythrold progenitors in a patient with agnagenic myeloid metaplasia
Hua-Kang Wu,Shigeru Chiba,Ken Inamori,Hiroyuki Mano,Tsuyoshi Tange,Yoshio Yazaki,Hisamaru Hirai,Mark D. Minden +7 more
Journal ArticleDOI
A new era of the Asian clinical research network: a report from the ATLAS international symposium.
Mitsumi Terada,K. Nakamura,Tomohiro Matsuda,Hitomi Sumiyoshi Okuma,Kazuki Sudo,Akhmal Yusof,Marcelo Severino B. Imasa,Ekaphop Sirachainan,Pham Tuan Anh,Yasuhiro Fujiwara,H. Yamamoto,Pei Jye Voon,Kulkanya Chokephaibulkit,Tatsuhiro Shibata,Manami Inoue,Hiroyuki Mano,Tatsunori Shimoi,Virote Sriuranpong,Kan Yonemori,Kazuaki Shimada +19 more
TL;DR: In the first Asian Clinical Trials Network for Cancers (ATLAS) international symposium that was held on 24 April 2022, in Bangkok, Thailand, and hosted by the National Cancer Center Hospital (NCCH), co-hosted by the Pharmaceuticals and Medical Devices Agency (PMDA), Clinical Research Malaysia (CRM), and the Thai Society of Clinical Oncology (TSCO), and supported by Embassy of Japan in Thailand as mentioned in this paper .
Journal ArticleDOI
High-Throughput Functional Evaluation of MAP2K1 Variants in Cancer
Sho Mizuno,Masachika Ikegami,Takafumi Koyama,Kuniko Sunami,Dai Ogata,Hidenori Kage,Mitsuru Yanagaki,Hiroshi Ikeuchi,Toshihide Ueno,Michihiro Tanikawa,Katsutoshi Oda,Yutaka Osuga,Hiroyuki Mano,Shinji Kohsaka +13 more
TL;DR: In this article , the transforming potential and drug sensitivity of 100 mitogen-activated protein kinase kinase 1 (MAP2K1) variants were evaluated using individual assays and the mixed-all-nominated-in-one method.
Journal ArticleDOI
Novel Calcium-Binding Ablating Mutations Induce Constitutive RET Activity and Drive Tumorigenesis
Junya Tabata,Takashi Nakaoku,Mitsugu Araki,Ryunosuke Yoshino,Shinji Kohsaka,Ayaka Otsuka,Masachika Ikegami,Ayako Ui,Shin Ichiro Kanno,Keiko Miyoshi,Shigeyuki Matsumoto,Yukari Sagae,Akira Yasui,Masakazu Sekijima,Hiroyuki Mano,Yasushi Okuno,Aikou Okamoto,Takashi Kohno +17 more
TL;DR: This study identifies calcium-binding ablating mutations as a novel type of oncogenic mutation of RET and indicates that in silico-driven annotation of VUSs of druggable oncogenes is a promising strategy to identify targetable driver mutations.
Journal ArticleDOI
An Asian multi-regional registry study of rare cancers: The MASTER KEY ASIA and MASTER KEY Japan projects.
Hitomi Sumiyoshi Okuma,Kan Yonemori,Chikashi Ishioka,Eishi Baba,Ichiro Kinoshita,Manabu Muto,Marcelo Severino B. Imasa,Pei Jye Voon,K. Y. de Almeida,Hwoei Fen Soo Hoo,Masahiko Ichimura,Chiharu Mizoguchi,Wataru Munakata,Shinji Kohsaka,Taro Shibata,Yasushi Yatabe,K. Nakamura,Hiroyuki Mano,H. Yamamoto +18 more
TL;DR: In this article , the authors used next-generation sequencing (NGS), immunohistochemical staining, fluorescent in situ hybridization (FISH), or single gene testing to identify the genomic and clinical diversity of rare cancers.